Denali Therapeutics Inc. (DNLI) Tops Q2 EPS by 8c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q2 EPS of ($0.59), $0.08 better than the analyst estimate of ($0.67).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• SpaceX (SPCX) reaches new intraday/all-time highs
• AstraZeneca receives FDA approval for Truqap prostate cancer treatment